Abstract
Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Volume: 8 Issue: 3
Author(s): G. A. Cabral and L. Griffin-Thomas
Affiliation:
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Abstract: Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Export Options
About this article
Cite this article as:
Cabral A. G. and Griffin-Thomas L., Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187153008785700118
DOI https://dx.doi.org/10.2174/187153008785700118 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research The Blood-brain Barrier and the Outer Blood-retina Barrier
Medicinal Chemistry Reviews - Online (Discontinued) Himalayan Plant Species as Pesticidal Agents
Mini-Reviews in Organic Chemistry Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Bioinformatics Comparison of G Protein of Isfahan Virus with the Same Proteins of Two Other Closely Related Viruses of the Genus Vesiculovirus
Protein & Peptide Letters Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Relation of Steatosis to Neurocognitive Function in People Living with HIV
Current HIV Research Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Inactivated- or Killed-Virus HIV/AIDS Vaccines
Current Drug Targets - Infectious Disorders A Review of Nanocarrier-Based CNS Delivery Systems
Current Drug Delivery An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Immunology and Epilepsy: Clinical and Experimental Evidence
Current Immunology Reviews (Discontinued) The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Effective Biomarkers for Proof-of-Concept
Current Medical Imaging Acute Symptomatic Seizures in Geriatric Patients with Multiple Risk Factors - A Diagnostic Challenge
Current Aging Science Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia
Current Neurovascular Research Acyclovir in the Treatment of Herpes Viruses – A Review
Current Medicinal Chemistry Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research